Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt

Research output: Contribution to journalArticlepeer-review

30 Citations (Scopus)


Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
Original languageEnglish
Pages (from-to)1-386
Number of pages386
JournalHealth Technology Assessment
Issue number29
Publication statusPublished - Jul 2013


  • Antibodies, Monoclonal, Humanized
  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Breast Neoplasms
  • Cost-Benefit Analysis
  • Female
  • Humans
  • Lung Neoplasms
  • Male
  • Models, Economic
  • Prostatic Neoplasms
  • Quality-Adjusted Life Years
  • Randomized Controlled Trials as Topic

Cite this